Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dociparstat sodium - Cantex Pharmaceuticals

Drug Profile

Dociparstat sodium - Cantex Pharmaceuticals

Alternative Names: CX-01; DSTAT; ODSH; PGX-100; PGX-ODSH-2013-AML-1

Latest Information Update: 07 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ParinGenix
  • Developer Cantex Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Heparins; Ischaemic heart disorder therapies; Polysaccharides
  • Mechanism of Action Cathepsin G inhibitors; Chemokine CXCL12 inhibitors; CXCR4 receptor antagonists; HMGB1 protein inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors; Platelet factor 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Pancreatic cancer
  • Phase I Brain injuries
  • No development reported Lung cancer; Solid tumours
  • Discontinued Acute coronary syndromes; Chronic obstructive pulmonary disease; Myocardial infarction; Reperfusion injury; Thrombocytopenia

Most Recent Events

  • 05 Nov 2019 Chimerix plans to schedule a End of Phase 2 Meeting with the US FDA for Acute myeloid leukaemia in the first quarter of 2020
  • 08 Aug 2019 Chimerix plans a phase III trial for Acute myeloid Leukemia in USA in mid-2020
  • 31 Jul 2019 Cantex Pharmaceuticals completes a phase II trial in Acute Myeloid Leukemia in USA (NCT02873338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top